In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.
Abstract
Background
Long-term outcomes of the self-expanding intra-annular Portico transcatheter aortic valve are not known.
Objectives
This study aimed to report the 5-year outcomes of the PORTICO IDE randomized controlled trial.
Methods
This multicenter trial randomized (1:1) patients with severe symptomatic aortic stenosis at high/extreme surgical risk to transcatheter aortic valve replacement (TAVR) with the self-expanding intra-annular valve (study valve) or Food and Drug Administration-approved commercially available valves (CAVs; balloon-expandable or self-expanding supra-annular platforms). Assessments of the primary safety endpoint (30 days) and the primary efficacy endpoint (1 year) have been previously reported. Prespecified clinical outcomes and hemodynamic valve parameters are presented through 5 years.
Results
We randomized 750 eligible patients (mean age: 83 years, 52.7% female) to the study valve (n = 381) or CAV (n = 369). Compared with CAV, the study valve showed similar 5-year all-cause mortality or stroke (55.6% vs 51.3%, P = 0.42). Cardiovascular mortality was numerically higher in the study valve group compared with the CAV group (33.4% vs 25.8%; P = 0.06). Naïve permanent pacemaker implantation was higher in the study valve group (36.6%) than the CAV group (20.3%; P < 0.0001) at 5 years. At 5 years, the study valve showed a lower mean transvalvular gradient (7.2 ± 3.0 vs 9.5 ± 6.5 mm Hg, P = 0.008), but similar valve area (1.78 ± 0.45 vs 1.71 ± 0.51 cm2, P = 0.40) compared to CAV.
Conclusions
In patients at high or extreme surgical risk, TAVR with the self-expanding intra-annular transcatheter heart valve had similar 5-year overall survival, stroke rates, and valve function compared with commercially available valves.
BACKGROUND
Most evidence for transcatheter aortic valve replacement (TAVR) for valve-in-valve procedures comes from balloon-expandable and supra-annular self-expanding valves. However, data on intra-annular self-expanding valves remain limited. The objectives of this registry were to evaluate the short- and midterm out...
Jorge F. Chavez, G. Tirado-Conte, Y. Kobari et al.· Journal of the American Hear...· 0 citations
BACKGROUND
Self-expanding valves appear to have superior hemodynamics compared with balloon-expandable valves for valve-in-valve transcatheter aortic valve replacement (ViV-TAVR).
OBJECTIVES
This study aimed to compare echocardiographic and clinical outcome data between supra-annular self-expanding valves (SASEVs) an...
Kuljit Singh, E. Dababneh, M. Matta et al.· JACC: Cardiovascular Interve...· 1 citation
The need for further investigations using larger cohorts and contemporary devices to validate long-term comparative outcomes of BEV and SEV in patients with SAA is underscore the need for further investigations using larger cohorts and contemporary devices to validate long-term comparative outcomes.
T. Ryuzaki, Kentaro Hayashida, Kei Kamata et al.· Cardiovascular Intervention...· 0 citations
In a national registry, redo-TAVR with the Evolut platform was associated with low procedural complication rates and clinical outcomes comparable with those observed with native TAVR and support redo-TAVR with Evolut as a feasible and effective treatment strategy in appropriately selected patients.
Toby Rogers, V. Bapat, S. Chetcuti et al.· JACC: Cardiovascular Interve...· 1 citation
Patients with small aortic annuli undergoing transcatheter aortic valve implantation (TAVI) are at risk of higher residual transvalvular gradients. Evidence on the performance of new‐generation intra‐annular self‐expanding valves in this anatomical setting remains limited.
M. Casenghi, S. Corradetti, P. Paolisso et al.· Catheterization and cardiova...· 0 citations
Patients with large aortic annuli are a more challenging subgroup for transcatheter aortic valve implantation (TAVI), and data on long‐term outcomes are sparse.
P. Alexiou, F. Moccetti, Stephanie Brunner et al.· Catheterization and cardiova...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.